EirGenix (6589) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 台康生技

EirGenix (6589) reported revenue of NT$271.7 million for Oct 2026, +287.9% year on year and +131.5% from the previous month. Revenue for Jan–Oct 2026 was NT$1.39 billion (+94.7% year on year).

Revenue for Oct 2026 was a record high (previous high: Nov 2023, NT$256.4 million). →

Year-on-year revenue growth: 6 months in a row. →

In Oct 2026, it ranked No. 36 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$60.3 million24/10Nov 2024 NT$95.9 millionDec 2024 NT$138.4 millionJan 2025 NT$50.1 millionFeb 2025 NT$42.3 million25/02Mar 2025 NT$89.5 millionApr 2025 NT$97.6 millionMay 2025 NT$74.7 millionJun 2025 NT$58.3 million25/06Jul 2025 NT$74.6 millionAug 2025 NT$72.5 millionSep 2025 NT$82 millionOct 2025 NT$70 million25/10Nov 2025 NT$135.8 millionDec 2025 NT$157.8 millionJan 2026 NT$108.8 millionFeb 2026 NT$85 million26/02Mar 2026 NT$114.7 millionApr 2026 NT$82.2 millionMay 2026 NT$116.8 millionJun 2026 NT$113.3 million26/06Jul 2026 NT$211.8 millionAug 2026 NT$163.7 millionSep 2026 NT$117.3 millionOct 2026 NT$271.7 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$271.7 million+287.9%+131.5%
Sep 2026NT$117.3 million+43.2%-28.3%
Aug 2026NT$163.7 million+125.9%-22.7%
Jul 2026NT$211.8 million+184.0%+86.9%
Jun 2026NT$113.3 million+94.3%-3.0%
May 2026NT$116.8 million+56.3%+42.1%
Apr 2026NT$82.2 million-15.8%-28.3%
Mar 2026NT$114.7 million+28.2%+35.0%
Feb 2026NT$85 million+100.6%-21.9%
Jan 2026NT$108.8 million+117.1%-31.1%
Dec 2025NT$157.8 million+14.0%+16.2%
Nov 2025NT$135.8 million+41.6%+93.9%
Oct 2025NT$70 million+16.1%-14.5%
Sep 2025NT$82 million+4.8%+13.1%
Aug 2025NT$72.5 million-11.1%-2.9%
Jul 2025NT$74.6 million-15.8%+27.9%
Jun 2025NT$58.3 million-4.2%-21.9%
May 2025NT$74.7 million-37.9%-23.5%
Apr 2025NT$97.6 million+49.8%+9.1%
Mar 2025NT$89.5 million+53.1%+111.3%
Feb 2025NT$42.3 million-10.2%-15.5%
Jan 2025NT$50.1 million-56.1%-63.8%
Dec 2024NT$138.4 million+30.3%+44.3%
Nov 2024NT$95.9 million-62.6%+59.0%
Oct 2024NT$60.3 million-35.8%-22.9%

Jan–Oct 2026 cumulative: NT$1.39 billion (+94.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: EirGenix vs PEC / EirGenix vs Lotus Pharm / EirGenix vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

本月:EG1206A達成里程碑依完工比例認列授權收入及CDMO業務成長。本年:自有產品授權金逐步認列及CDMO業務成長。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16